GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ORB-011 overview
ORB-011 is under development for the treatment of solid tumors including triple-negative breast cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer squamous cell carcinoma, metastatic melanoma, bladder cancer, gastric cancer, transitional cell cancer (urothelial cell cancer), esophageal cancer, kidney cancer (renal cell cancer), ovarian cancer, liver cancer, colorectal cancer. It is administered through intravenous route.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Orionis Biosciences overview
Orionis Biosciences is a biotechnology company that discover and develops drugs for the treatment of oncology, immunotherapies and diseases with high unmet medical needs. The company is headquartered in Waltham, Massachusetts, the US.
For a complete picture of ORB-011’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#ORB011 #Orionis #Biosciences #Liver #Cancer #Likelihood #Approval
